Aethlon Medical (NASDAQ:AEMD – Get Free Report) and Becton, Dickinson and Company (NYSE:BDX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.
Profitability
This table compares Aethlon Medical and Becton, Dickinson and Company’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aethlon Medical | N/A | -160.36% | -115.74% |
| Becton, Dickinson and Company | 8.47% | 15.74% | 7.29% |
Volatility & Risk
Aethlon Medical has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aethlon Medical | 0 | 0 | 1 | 0 | 3.00 |
| Becton, Dickinson and Company | 0 | 0 | 7 | 0 | 3.00 |
Aethlon Medical currently has a consensus price target of $7.00, suggesting a potential upside of 930.17%. Becton, Dickinson and Company has a consensus price target of $283.00, suggesting a potential upside of 23.39%. Given Aethlon Medical’s higher probable upside, research analysts clearly believe Aethlon Medical is more favorable than Becton, Dickinson and Company.
Earnings & Valuation
This table compares Aethlon Medical and Becton, Dickinson and Company”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aethlon Medical | $570,000.00 | 16.64 | -$12.21 million | ($2.82) | -0.24 |
| Becton, Dickinson and Company | $20.18 billion | 3.30 | $1.71 billion | $6.02 | 38.10 |
Becton, Dickinson and Company has higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
2.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of Aethlon Medical shares are owned by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Becton, Dickinson and Company beats Aethlon Medical on 9 of the 13 factors compared between the two stocks.
About Aethlon Medical
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
